Investigational Drug Information for Masitinib
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Masitinib?
Masitinib is an investigational drug.
There have been 36 clinical trials for Masitinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 25th 2008.
The most common disease conditions in clinical trials are Sclerosis, Mastocytosis, and Gastrointestinal Stromal Tumors. The leading clinical trial sponsors are AB Science and [disabled in preview].
Summary for Masitinib
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 902 |
WIPO Patent Applications | 709 |
Japanese Patent Applications | 240 |
Clinical Trial Progress | Phase 3 (2008-11-25) |
Vendors | 87 |
Recent Clinical Trials for Masitinib
Title | Sponsor | Phase |
---|---|---|
Masitinib for the Treatment of Severe Mast Cell Activation Syndrome | AB Science | Phase 2 |
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis | AB Science | Phase 3 |
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 | AB Science | Phase 2 |
Clinical Trial Summary for Masitinib
Top disease conditions for Masitinib
Top clinical trial sponsors for Masitinib
US Patents for Masitinib
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |